# Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes

> **NCT05174507** · PHASE2 · WITHDRAWN · sponsor: **University Hospital, Basel, Switzerland**

## Conditions studied

- Postprandial Hypoglycemia

## Interventions

- **DRUG:** empagliflozin
- **DRUG:** anakinra
- **OTHER:** saline subcutaneous (s.c.) (placebo)
- **OTHER:** tablet per oral (p.o.) (placebo)

## Key facts

- **NCT ID:** NCT05174507
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06-24
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-05-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor- Investigator decision
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05174507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05174507, "Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05174507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*